Hematologist
CION Cancer Clinics
AML survival: what the numbers mean for you | CION Cancer Clinics
No single survival rate applies to your family member. AML outlook in India varies widely with age, the genetic type of the leukaemia, general health and how it responds to the first treatment. Online figures mix very different people and older treatments. This page explains what shapes the outlook, when the picture becomes clearer, and how to ask your haematologist for an honest answer. At CION Cancer Clinics, every leukaemia, MDS and MPN case is reviewed by our haematologist and discussed at a tumour board before a plan is agreed.
BP
Medically reviewed by Dr. Basudev PokhrelConsultant Haematologist · last reviewed September 2026, next review due September 2027
17+specialists on panel
15,000+patients treated
35+centres across Telangana & AP
4.8★ / 800+Google rating
On this page
- What is the survival rate for AML in India?
- What actually shapes the outlook in AML?
- When does the picture become clearer?
- How do you ask the haematologist about outlook?
- What can a survival statistic tell you, and what can it not?
- What do families often believe about AML outlook?
- What do the survival words mean?
- Common questions about AML survival
The short answer
What is the survival rate for AML in India?
There is no single survival figure that applies to your family member. Outlook in AML varies enormously with age, the genetic type of the leukaemia, general health and how it responds to the first treatment. Your haematologist is the only person who can give you a picture for this person.
Why we do not quote a number here
Survival figures you find online come from groups of people treated years ago, often in other countries, with different ages, leukaemia types and treatments. Averaging a young person with favourable-risk AML and a frail older adult with adverse-risk AML produces a number that describes neither. Read alone, it can frighten or falsely reassure.
What Indian data can and cannot show
India does not yet have complete national figures for AML outcomes. Published results mostly come from individual large centres, and they reflect who could reach those centres and afford full treatment. Delays in diagnosis, infections during treatment and stopping treatment because of cost all affect results in India. None of that tells you what will happen to one person who is being treated now.
Why older numbers can mislead
Studies that report long-term survival have to follow people for many years, so by the time they are published the treatments have often moved on. Newer medicines, better genetic testing and better infection care have changed AML treatment in the last decade. A figure from an old study may not reflect the options available to your family member today.
Outlook is not fixed at diagnosis. It is updated as test results and treatment responses come in.What matters
What actually shapes the outlook in AML?
These are the things your haematologist will look at. Together they say far more than any average.
The genetic type
Chromosome and gene tests on the marrow sort AML into favourable, intermediate and adverse risk groups. This is often the strongest single guide.
Examples you may see
- NPM1, which is often favourable
- FLT3, which can change the plan
- Complex chromosome changes
Age and general health
Younger, fitter people can usually have more intensive treatment. Heart, kidney and lung problems limit what can be given safely.
Response to treatment
Reaching remission after the first course, and having no leukaemia found on sensitive residual disease tests, are encouraging signs.
A slow response changes the plan, not always the outlook.Where AML came from
AML that follows an earlier blood disorder or earlier cancer treatment tends to be harder to treat than AML that appears on its own.
Getting through treatment safely
Serious infections during the low-count weeks are a major risk. Quick treatment of fever, clean food and water, and a family that acts fast all help people reach the end of treatment.
Not sure whether this applies to you?
Ask an oncologistOver time
When does the picture become clearer?
At diagnosis
Age, health and early blood results give a first, rough idea. Genetic results usually follow within days to weeks and sharpen it. Early talk of outlook is often cautious for this reason.
After induction
The marrow test after the first treatment shows whether remission was reached. This is one of the most important turning points. Ask the team what the result means for the plan and the outlook.
During consolidation
Residual disease tests and the decision about transplant refine the picture again. The team can now speak more specifically.
After treatment ends
The longer someone stays in remission, the lower the chance of the leukaemia returning. Follow-up visits continue.
Talking to the team
How do you ask the haematologist about outlook?
It is fair to ask directly. Most haematologists would rather answer an honest question than have a family guess from the internet. You can decide how much detail you want, and the patient may want a different amount from the rest of the family.
Questions that get useful answers
What risk group is the leukaemia in? What are we aiming for with this treatment, long-term remission or control? What would make you more or less hopeful over the next few weeks? What happens if the first treatment does not work? These questions give you a plan, not just a statistic.
When the news is hard
Sometimes the honest answer is that treatment is unlikely to hold the leukaemia back for long. Knowing this can help the family decide what matters most: time at home, fewer admissions, being together. Asking for a counsellor or palliative care team, which focuses on comfort and quality of life, is not giving up.
If the patient does not want numbers, respect that, and ask the doctor to speak with the family separately.Leave a number, we will call you
One field. No form to fill in, and no charge for the call.
Side by side
What can a survival statistic tell you, and what can it not?
What a statistic can tell you
What it cannot tell you
How a large group did on average
How one person will do
Results from treatments used years ago
The effect of newer medicines now in use
Broad differences between risk groups
Where your family member sits within that group
Patterns in the country where the study was done
Outcomes for a person treated in Telangana today
Commonly believed
What do families often believe about AML outlook?
"Leukaemia always means only a few months."
Without treatment, AML is often fast. With treatment, many people reach remission, and some stay in long-term remission. The outlook depends heavily on the type and the treatment possible.
"The number we read online is his number."
An online figure mixes very different people together. Your haematologist can tell you what the tests say for this person, which is far more useful.
"Remission means the danger is over."
Remission is a very good step, but AML can return. That is why consolidation and follow-up matter, even when the person feels well.
"Stopping treatment halfway makes no difference."
Incomplete treatment is one of the reasons outcomes differ in India. If cost, travel or side effects are making it hard, tell the team before stopping.
In reports and studies
What do the survival words mean?
- Overall survival
- The share of people in a study still alive at a set time after diagnosis or treatment.
- Event-free survival
- The share still alive without the leukaemia returning or treatment failing at a set time.
- Remission
- No leukaemia seen in the marrow and blood counts recovered. It is not the same as the disease being gone for good.
- Relapse
- The leukaemia coming back after remission.
- Risk group
- Favourable, intermediate or adverse, based mainly on genetic tests of the leukaemia.
Questions we are asked
Common questions about AML survival
Can AML be treated successfully?
Yes, for many people. With intensive treatment, and sometimes a transplant, some people stay in long-term remission. For others, treatment controls the leukaemia for a period. Which of these is realistic depends on the leukaemia type, age and health. Your haematologist can explain what the aim is for your family member.
Is the outlook worse in India than abroad?
Published Indian results vary widely between centres. Late diagnosis, serious infections during treatment and stopping treatment for cost reasons can all worsen results. Access to timely, complete treatment and good infection care makes a real difference, wherever a person is treated.
Does a transplant improve survival?
For some people with intermediate or adverse-risk AML, a transplant in first remission lowers the chance of relapse. It also carries serious risks of its own. It is not helpful for everyone. The haematologist weighs the risk of the leukaemia against the risk of transplant for each person.
What does it mean if AML comes back?
Relapsed AML is harder to treat, and the options depend on how long remission lasted, the genetic type and general health. Some people reach a second remission. The team will explain what is possible. Honest conversations about goals become especially important at this stage.
Is AML in children different?
Yes. Children with AML generally tolerate intensive treatment better and are treated on specific children's protocols by paediatric specialists. Figures for adults do not apply to children. Ask the child's treating team for a picture that fits your child.
Does diet or ayurveda change the outlook?
No food, supplement or herbal remedy has been shown to treat AML. Some can interact with chemotherapy or harm the liver. Good nutrition helps a person cope with treatment. Tell the team before starting any supplement or traditional medicine.
How long does follow-up continue after treatment?
Follow-up usually continues for several years, with blood tests at regular visits that become less frequent over time. The aim is to spot any return early and to check for late effects of treatment. Your haematologist will set the schedule.
Can CION give a second opinion on the outlook?
Yes. CION's haematology team, led by Dr. Basudev Pokhrel, can review the marrow, genetic and treatment reports and take complex cases to a tumour board. Bring every report you have. Where a transplant assessment is needed, the team coordinates with qualified centres.
Your Haematologist
Meet CION's haematologist. One specialist for your blood report and your plan.
Dr. Basudev Pokhrel reviews blood counts, transfusion needs and blood disorders, and works with the CION tumour board on blood cancers.
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
Sources
- Cancer Research UK — Survival for acute myeloid leukaemia (AML)
- National Cancer Institute — Adult Acute Myeloid Leukemia Treatment (PDQ) - Patient Version
- American Cancer Society — Acute Myeloid Leukemia (AML)
- Cancer.Net — Leukemia - Acute Myeloid - AML
This page is general information, not a prescription. Do not change or stop any treatment based on what you read here. If anything is worrying you, contact your own treating team — or call our helpline and we will help you reach the right specialist.
Keep reading
Related pages
Talk to us
Want an honest picture for your family member?
Tell us what has been found so far. CION's haematology team will review the reports and explain what they mean. One helpline serves every CION centre.